JP4511183B2 - 神経変性疾患および心臓血管疾患の治療 - Google Patents
神経変性疾患および心臓血管疾患の治療 Download PDFInfo
- Publication number
- JP4511183B2 JP4511183B2 JP2003554183A JP2003554183A JP4511183B2 JP 4511183 B2 JP4511183 B2 JP 4511183B2 JP 2003554183 A JP2003554183 A JP 2003554183A JP 2003554183 A JP2003554183 A JP 2003554183A JP 4511183 B2 JP4511183 B2 JP 4511183B2
- Authority
- JP
- Japan
- Prior art keywords
- disease
- neurodegenerative
- pharmaceutical composition
- caffeic acid
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
RlおよびR2は、それぞれ独立して、C1−8アルキレン、C2−8アルケニレンであるか、または削除される;
A1およびA2は、それぞれ独立して、ハロゲン、−CN、−NO2、−OH、−SH、−OR3、−SR3、−R3、−R3−OR4、−C(O)R3、−S(O)R3、−S(O)2R3、−NR4R5、−C(O)OR3、−C(O)NR4R5、−O(O)CR4、または−NR4(O)CR5で単置換または複数置換(例、二置換または三置換)されていてもよいアリールまたはヘテロアリールであり;および
XおよびYは、独立して、O、SまたはNR6である。
[式中、R3はそれぞれC1−4アルキルであり、R4、R5およびR6は、それぞれ独立して、HまたはC1−4アルキルである。]
[式中、A1、A2、R1、R2、XおよびYはそれぞれ上記で定義した通りである。]
Claims (3)
- 心筋症を治療するための医薬組成物である、請求項1に記載の医薬組成物。
- パーキンソン病、ハンチントン病、アルツハイマー病または筋萎縮性側索硬化症を治療するための医薬組成物である、請求項1に記載の医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33921501P | 2001-12-10 | 2001-12-10 | |
PCT/US2002/039458 WO2003053425A1 (en) | 2001-12-10 | 2002-12-10 | Treatment of neurodegenerative and cardiovascular disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005513100A JP2005513100A (ja) | 2005-05-12 |
JP4511183B2 true JP4511183B2 (ja) | 2010-07-28 |
Family
ID=23328006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003554183A Expired - Fee Related JP4511183B2 (ja) | 2001-12-10 | 2002-12-10 | 神経変性疾患および心臓血管疾患の治療 |
Country Status (9)
Country | Link |
---|---|
US (2) | US20030139458A1 (ja) |
EP (1) | EP1461025B1 (ja) |
JP (1) | JP4511183B2 (ja) |
CN (1) | CN100358515C (ja) |
AT (1) | ATE517617T1 (ja) |
AU (1) | AU2002351341A1 (ja) |
CA (1) | CA2466928A1 (ja) |
TW (1) | TWI335220B (ja) |
WO (1) | WO2003053425A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070208087A1 (en) | 2001-11-02 | 2007-09-06 | Sanders Virginia J | Compounds, compositions and methods for the treatment of inflammatory diseases |
SI2527315T1 (sl) | 2002-05-31 | 2014-06-30 | Proteotech Inc., | Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen |
US20040167217A1 (en) * | 2003-02-26 | 2004-08-26 | Giovanni Scapagnini | Neuroprotective effects of polyphenolic compounds |
WO2007084383A2 (en) * | 2006-01-13 | 2007-07-26 | University Of South Carolina | Method and composition for the treatment of parkinson's disease |
EP2125712B1 (en) * | 2006-12-04 | 2014-07-23 | Novotyr Therapeutics Ltd. | Novel protein kinase modulators and therapeutic uses thereof |
US8637575B2 (en) | 2008-06-05 | 2014-01-28 | Novotyr Therapeutics Ltd. | Modulators of protein kinase signaling |
CN101941907B (zh) * | 2010-05-28 | 2015-04-01 | 毛腾淑 | 4-叔丁基苄基-3,4-二羟基肉桂酸酯及其用途和制备方法 |
EP2629766B1 (en) * | 2010-10-18 | 2017-02-22 | Chemigen | Combination therapy |
WO2012068038A2 (en) * | 2010-11-15 | 2012-05-24 | Chemigen | Caffeic acid derivatives and their use in improving neuronal cell viability |
WO2015008206A1 (en) | 2013-07-14 | 2015-01-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Igf-1r signaling pathway inhibitors useful in the treatment of neurodegenerative diseases |
EP3750530A1 (en) | 2015-02-05 | 2020-12-16 | TyrNovo Ltd. | Combinations of irs/stat3 dual modulators and anti-cancer agents for treating cancer |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2721398A1 (de) * | 1976-05-19 | 1977-12-01 | Ciba Geigy Ag | Alkylphenol-stabilisatoren |
JPS62294634A (ja) * | 1986-04-11 | 1987-12-22 | ワ−ナ−−ランバ−ト・コンパニ− | ジアリ−ルアルカノイドおよびその製法 |
US4959503A (en) * | 1986-04-11 | 1990-09-25 | Warner-Lambert Company | Diarylalkanoids having activity as lipoxygenase inhibitors |
JPH0678286B2 (ja) * | 1988-03-18 | 1994-10-05 | 三井東圧化学株式会社 | ジヒドロカフェイン酸誘導体およびそれを有効成分として含有する治療剤 |
DE3920616A1 (de) * | 1989-06-23 | 1991-01-03 | Boehringer Mannheim Gmbh | Arzneimittel, enthaltend di-tert.-butylhydroxyphenyl-derivate sowie neue derivate |
DE4126662A1 (de) * | 1991-08-13 | 1993-02-18 | Boehringer Mannheim Gmbh | Neue 3,5-di-tert.butyl-4-hydroxyphenyl-derivate, verfahren zu ihrer herstellung und arzneimittel |
WO1997023202A1 (en) * | 1995-12-22 | 1997-07-03 | STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON | Subtype-selective nmda receptor ligands and the use thereof |
EP0998275A4 (en) * | 1996-09-05 | 2003-05-02 | Res Dev Foundation | INHIBITION OF THE NUCLEAR TRANSCRIPTION FACTOR NF-kappaB BY THE PHENETHYLIC ESTER OF CAFEIC ACID, DERIVATIVES OF THIS ESTER, CAPSAICIN (8-METHYL-N-VANILLYLE-6-NONEAMIDE) AND RESINIFERATOXIN |
TW466115B (en) * | 1996-12-10 | 2001-12-01 | American Home Prod | Pharmaceutical composition of antioxidant from equilenin |
CN1159061C (zh) * | 1997-02-15 | 2004-07-28 | 千年药物公司 | 通过nf-kappab的抑制治疗梗塞 |
GB9801398D0 (en) * | 1998-01-22 | 1998-03-18 | Anggard Erik E | Chemical compounds |
WO2001021206A1 (fr) * | 1999-09-17 | 2001-03-29 | Suntory Limited | MOYENS DE PREVENTION OU REMEDES CONTRE LA MYOCARDITE, LA CARDIOMYOPATHIE DILATEE ET L'INSUFFISANCE CARDIAQUE CONTENANT DES INHIBITEURS NF-λB EN TANT QU'INGREDIENT ACTIF |
-
2002
- 2002-12-10 WO PCT/US2002/039458 patent/WO2003053425A1/en active Application Filing
- 2002-12-10 JP JP2003554183A patent/JP4511183B2/ja not_active Expired - Fee Related
- 2002-12-10 CA CA002466928A patent/CA2466928A1/en not_active Abandoned
- 2002-12-10 CN CNB02823183XA patent/CN100358515C/zh not_active Expired - Fee Related
- 2002-12-10 TW TW091135703A patent/TWI335220B/zh not_active IP Right Cessation
- 2002-12-10 AT AT02786994T patent/ATE517617T1/de not_active IP Right Cessation
- 2002-12-10 AU AU2002351341A patent/AU2002351341A1/en not_active Abandoned
- 2002-12-10 US US10/316,145 patent/US20030139458A1/en not_active Abandoned
- 2002-12-10 EP EP02786994A patent/EP1461025B1/en not_active Expired - Lifetime
-
2010
- 2010-02-18 US US12/708,401 patent/US8575215B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1461025A1 (en) | 2004-09-29 |
JP2005513100A (ja) | 2005-05-12 |
WO2003053425A1 (en) | 2003-07-03 |
TW200301100A (en) | 2003-07-01 |
EP1461025B1 (en) | 2011-07-27 |
AU2002351341A1 (en) | 2003-07-09 |
TWI335220B (en) | 2011-01-01 |
ATE517617T1 (de) | 2011-08-15 |
EP1461025A4 (en) | 2009-07-29 |
US8575215B2 (en) | 2013-11-05 |
US20030139458A1 (en) | 2003-07-24 |
CN1589137A (zh) | 2005-03-02 |
CA2466928A1 (en) | 2003-07-03 |
CN100358515C (zh) | 2008-01-02 |
US20100160433A1 (en) | 2010-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8575215B2 (en) | Treatment of neurodegenerative and cardiovascular disorders | |
AU2005228685B2 (en) | Hydrazide-containing CFTR inhibitor compounds and uses thereof | |
US4904681A (en) | D-cycloserine and its prodrugs as cognitive enhancers | |
SK78896A3 (en) | 2,4-disulfonyl-alpha-phenyl-tert.-butyl nitrone or its pharmaceutically appropriate salt and pharmaceutical composition containing them | |
WO2020259528A1 (zh) | 治疗特发性肺纤维化的方法 | |
BR112020019325A2 (pt) | Método de tratamento de doença fibrótica | |
JPS62158210A (ja) | L−ド−パの直腸吸収形態 | |
BRPI1013259B1 (pt) | Moduladores lxr | |
US9840483B2 (en) | Radiomitigating pharmaceutical formulations | |
JP2024015132A (ja) | O-環状フィトスフィンゴシン-1-フォスフェートを含むパーキンソン病の予防又は治療用組成物 | |
JP2010514734A (ja) | 腸障害の治療のためのイソソルビドモノニトレート誘導体 | |
EP1073430B1 (en) | Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders | |
EA003251B1 (ru) | ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ п-АМИНОФЕНОЛА ДЛЯ ПРИГОТОВЛЕНИЯ ФАРМАЦЕВТИЧЕСКИХ КОМПОЗИЦИЙ, ИСПОЛЬЗУЕМЫХ ПРИ ЛЕЧЕНИИ НЕЙРОДЕГЕНЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
KR910018348A (ko) | 술포닐아미노치환 비시클로환계 히드록삼산 유도체 | |
US20130225545A1 (en) | Porphyrin treatment of neurodegenerative diseases | |
US5854248A (en) | Nefazodone: use in migraine prophylaxis | |
JP7295145B2 (ja) | 神経変性疾患を治療するための医薬及びその使用 | |
BR0214293A (pt) | Composto e métodos para tratar um paciente que tenha, ou de prevenir um paciente de adquirir, uma doença ou condição e para produzir um composto ou um sal ou éster farmaceuticamente aceitável do mesmo | |
ES2278930T3 (es) | Uso de un derivado de la piridazinona en el tratamiento de una insuficiencia cardiaca congestiva. | |
JP2007518673A (ja) | 2−アミノベンゾイル誘導体 | |
US20220287993A1 (en) | Pharmaceutical composition comprising hdac inhibitor and anti-pd1 antibody or anti pd-l1 antibody | |
US20210338694A1 (en) | Sos1 allosteric site targeting | |
FR2722987A1 (fr) | Utilisation de l'eliprodil et de ses enantiomeres pour la preparation de medicaments utiles dans la prevention des neuropathiesinduites par des agentsanticancereux | |
JPH04128225A (ja) | 抗腫瘍剤 | |
Rorarius et al. | The effect of diclofenac and ketoprofen on halothane MAC in rabbit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051117 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090526 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20090806 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090806 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090825 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090826 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090915 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100209 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100312 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100406 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100506 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130514 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |